source
- Merck and Moderna’s melanoma vaccine shows positive Phase 3 results, boosting investor confidenceMerck and Moderna announced that their personalized melanoma vaccine met the primary endpoint of recurrence‑free survival in a Phase 3 trial when given together with Keytruda. The study showed pati…
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…